

Nezos Andrianos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2660878/publications.pdf>

Version: 2024-02-01

50
papers

1,331
citations

430874

18
h-index

345221

36
g-index

50
all docs

50
docs citations

50
times ranked

1912
citing authors

#	ARTICLE	IF	CITATIONS
1	Subclinical atherosclerosis profiles in rheumatoid arthritis and primary Sjögren's syndrome: the impact of BAFF genetic variations. <i>Rheumatology</i> , 2023, 62, 958-968.	1.9	2
2	Milk Fat Globule Epidermal Growth Factor 8 (MFGE8) Gene Variants in Rheumatoid Arthritis and Sjögren's Syndrome. <i>Journal of Clinical Medicine</i> , 2022, 11, 1180.	2.4	2
3	Expression of APOBEC family members as regulators of endogenous retroelements and malignant transformation in systemic autoimmunity. <i>Clinical Immunology</i> , 2021, 223, 108649.	3.2	9
4	B-cell Activating Factor Polymorphisms in Rheumatoid Arthritis-Associated Atherosclerosis. <i>Mediterranean Journal of Rheumatology</i> , 2021, 32, 179.	0.8	0
5	Leukocyte Immunoglobulin-Like Receptor A3 (LILRA3): A Novel Marker for Lymphoma Development among Patients with Young Onset Sjögren's Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 644.	2.4	7
6	Expression of tissue remodelling, inflammation- and angiogenesis-related factors after eccentric exercise in humans. <i>Molecular Biology Reports</i> , 2021, 48, 4047-4054.	2.3	6
7	Lipoprotein-Associated Phospholipase A2: A Novel Contributor in Sjögren's Syndrome-Related Lymphoma?. <i>Frontiers in Immunology</i> , 2021, 12, 683623.	4.8	6
8	Scleroderma specific autoantibodies and MS-like manifestations: A novel association?. <i>Autoimmunity Reviews</i> , 2021, 20, 102871.	5.8	0
9	+3179G/A Insulin-Like Growth Factor-1 Receptor Polymorphism: A Novel Susceptibility Contributor in Anti-Ro/SSA Positive Patients with Sjögren's Syndrome: Potential Clinical and Pathogenetic Implications. <i>Journal of Clinical Medicine</i> , 2021, 10, 3960.	2.4	5
10	TREX1 variants in Sjogren's syndrome related lymphomagenesis. <i>Cytokine</i> , 2020, 132, 154781.	3.2	18
11	Molecular and clinical spectrum of four pedigrees of TRAPS in Greece: results from a national referral center. <i>Rheumatology</i> , 2020, 59, 1241-1246.	1.9	6
12	Association Between DNA Damage Response, Fibrosis and Type I Interferon Signature in Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2020, 11, 582401.	4.8	34
13	Type I and II Interferon Signatures Can Predict the Response to Anti-TNF Agents in Inflammatory Bowel Disease Patients: Involvement of the Microbiota. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1543-1553.	1.9	16
14	Assessing the practice of LuPOR for poor responders: a prospective study evaluating follicular fluid cfDNA levels during natural IVF cycles. <i>Journal of Assisted Reproduction and Genetics</i> , 2020, 37, 1183-1194.	2.5	8
15	The Role of Novel Autoantibodies in the Diagnostic Approach and Prognosis of Patients with Raynaud's Phenomenon. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 427.	0.8	0
16	Diagnosis and Management of a Young Girl With Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) Linked to a Novel Mutation. <i>Cureus</i> , 2020, 12, e10766.	0.5	0
17	Independent association of low IFN γ 1 gene expression and type I IFN score/IFN γ 1 ratio with obstetric manifestations and triple antiphospholipid antibody positivity in primary antiphospholipid syndrome. <i>Clinical Immunology</i> , 2019, 209, 108265.	3.2	13
18	Genetic contributors and soluble mediators in prediction of autoimmune comorbidity. <i>Journal of Autoimmunity</i> , 2019, 104, 102317.	6.5	15

#	ARTICLE	IF	CITATIONS
19	FRI0012â€¦THE CLINICAL SPECTRUM AND PEDIGREE ANALYSIS OF TRAPS IN GREECE, INCLUDING A NOVEL MUTATION-RESULTS FORM A NATIONAL REFERRAL CENTRE. , 2019, , .		0
20	AB0183â€¦THE ROLE OF THE PHOSPHOLIPASE LP-PLA2 ACTIVITY IN SJOGRENâ€™S SYNDROME RELATED LYMPHOMAGENESIS: A NEW SERUM BIOMARKER?. , 2019, , .		1
21	THU0204â€¦ASSOCIATION OF LILRA3 GENE WITH LYMPHOMAGENESIS RISK IN YOUNG SS PATIENTS. , 2019, , .		2
22	THU0228â€¦EXPRESSION OF APOBEC FAMILY MEMBERS AS REGULATORS OF ENDOGENOUS RETROELEMENTS AND MALIGNANCY IN SYSTEMIC LUPUS ERYTHEMATOSUS AND SJÅ–GRENâ€™S SYNDROME. , 2019, , .		1
23	AB0181â€¦ASSOCIATION BETWEEN SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) OF THE BAFF GENE AND FATIGUE IN PRIMARY SJÅ–GRENâ€™S SYNDROME. , 2019, , .		0
24	AB0182â€¦RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B LIGAND (RANKL)/RANK AND OSTEOPROTEGERIN (OPG) PATHWAY ACTIVATION IN SJÅ–GRENâ€™S SYNDROME. , 2019, , .		0
25	Defective regulation of L1 endogenous retroelements in primary Sjogren's syndrome and systemic lupus erythematosus: Role of methylating enzymes. Journal of Autoimmunity, 2018, 88, 75-82.	6.5	65
26	TNFAIP3 F127C Coding Variation in Greek Primary Sjogrenâ€™s Syndrome Patients. Journal of Immunology Research, 2018, 2018, 1-8.	2.2	24
27	B-cell activating factor and related genetic variants in lupus related atherosclerosis. Journal of Autoimmunity, 2018, 92, 87-92.	6.5	51
28	Autoantibodies to ox-LDL in SjÅ–gren's syndrome: are they atheroprotective?. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 61-67.	0.8	5
29	Analysis of NLRP3, MVK and TNFRSF1A variants in adult Greek patients with autoinflammatory symptoms. Clinical and Experimental Rheumatology, 2018, 36, 86-89.	0.8	9
30	Antibodies against citrullinated alpha enolase peptides in primary Sjogren's syndrome. Clinical Immunology, 2017, 183, 300-303.	3.2	21
31	Type I interferonopathy in a young adult. Rheumatology, 2017, 56, 2241-2243.	1.9	17
32	MTHFR gene variants and non-MALT lymphoma development in primary Sjogrenâ€™s syndrome. Scientific Reports, 2017, 7, 7354.	3.3	28
33	07.08â€¦Contribution of mthfr gene polymorphisms in primary sjÅ–grenâ€™s syndrome related lymphomagenesis. , 2017, , .		0
34	07.09â€¦Influence of b-cell activating factor genetic variants in sjÅ–grenâ€™s syndrome related atherosclerosis. , 2017, , .		0
35	Type I interferon signature may influence the effect of belimumab on immunoglobulin levels, including rheumatoid factor in SjÅ–gren's syndrome. Clinical and Experimental Rheumatology, 2017, 35, 719-720.	0.8	3
36	Expression of Long Interspersed Nuclear Element 1 Retroelements and Induction of Type I Interferon in Patients With Systemic Autoimmune Disease. Arthritis and Rheumatology, 2016, 68, 2686-2696.	5.6	149

#	ARTICLE	IF	CITATIONS
37	Fatigue in Primary Sjögren's Syndrome: Clinical, Laboratory, Psychometric, and Biologic Associations. <i>Arthritis Care and Research</i> , 2016, 68, 123-131.	3.4	64
38	Increased frequency of the PTPN22W* variant in primary Sjogren's Syndrome: Association with low type I IFN scores. <i>Clinical Immunology</i> , 2016, 173, 157-160.	3.2	24
39	Contribution of Genetic Factors to Sjögren's Syndrome and Sjögren's Syndrome Related Lymphomagenesis. <i>Journal of Immunology Research</i> , 2015, 2015, 1-12.	2.2	31
40	Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis. <i>Journal of Autoimmunity</i> , 2015, 63, 47-58.	6.5	215
41	B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. <i>Journal of Autoimmunity</i> , 2014, 51, 89-98.	6.5	99
42	Detection of circulating tumor cells in bladder cancer using multiplex PCR assays. <i>Anticancer Research</i> , 2014, 34, 7415-24.	1.1	12
43	Multiplex PCR-Based Detection of Circulating Tumor Cells in Lung Cancer Patients Using CK19, PTHrP, and LUNX Specific Primers. <i>Clinical Lung Cancer</i> , 2013, 14, 513-520.	2.6	15
44	New advances in the classification, pathogenesis and treatment of Sjogren's syndrome. <i>Current Opinion in Rheumatology</i> , 2013, 25, 623-629.	4.3	48
45	Subdivision of molecularly-classified groups by new gene signatures in breast cancer patients. <i>Oncology Reports</i> , 2012, 28, 2255-2263.	2.6	17
46	Preferential expression of IGF1Ec (MGF) transcript in cancerous tissues of human prostate: Evidence for a novel and autonomous growth factor activity of MGF E peptide in human prostate cancer cells. <i>Prostate</i> , 2010, 70, 1233-1242.	2.3	45
47	Detection of the circulating tumor cells in cancer patients. <i>Future Oncology</i> , 2010, 6, 1849-1856.	2.4	29
48	Molecular markers detecting circulating melanoma cells by reverse transcription polymerase chain reaction: methodological pitfalls and clinical relevance. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 1-11.	2.3	32
49	CD40/CD40L signaling and its implication in health and disease. <i>BioFactors</i> , 2009, 35, 474-483.	5.4	143
50	Detection of circulating tumor cells in bladder cancer patients. <i>Cancer Treatment Reviews</i> , 2009, 35, 272-279.	7.7	34